FDA approves Pfizer's Ibrance

FDA granted accelerated approval to Ibrance palbociclib ( PD-0332991) from Pfizer Inc. (NYSE:PFE) in combination with Femara letrozole as first-line treatment of

Read the full 221 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE